Published in New England Journal of Medicine · View the paper (DOI)
A new therapeutic option has been found for patients with a treatment-resistant tumor mutation called KRAS G12C. The sotorasib and panitumumab combination demonstrated superior progression-free survival rates compared to standard of care.
Coverage from 2 institutions